Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system
Deborah E Malden, John M Mclaughlin, Vennis Hong, Joseph Lewnard, Bradley K Ackerson, Laura Puzniak, Jeniffer S Kim, Harpreet Takhar, Timothy B Frankland, Jeff M Slezak, Sara Y Tartof
Scientific Reports, doi:10.1038/s41598-024-57633-7
A clear understanding of real-world uptake of nirmatrelvir-ritonavir for treatment of SARS-CoV-2 can inform treatment allocation strategies and improve interpretation of effectiveness studies. We used data from a large US healthcare system to describe nirmatrelvir-ritonavir dispenses among all SARS-CoV-2 positive patients aged ≥ 12 years meeting recommended National Institutes of Health treatment eligibility criteria for the study period between 1 January and 31 December, 2022. Overall, 10.9% (N = 34,791/319,900) of treatment eligible patients with SARS-CoV-2 infections received nirmatrelvir-ritonavir over the study period. Although uptake of nirmatrelvir-ritonavir increased over time, by the end of 2022, less than a quarter of treatment eligible patients with SARS-CoV-2 infections had received nirmatrelvir-ritonavir. Across patient demographics, treatment was generally consistent with tiered treatment guidelines, with dispenses concentrated among patients aged ≥ 65 years (14,706/63,921; 23.0%), and with multiple comorbidities (10,989/54,431; 20.1%). However, neighborhoods of lower socioeconomic status (upper third of neighborhood deprivation index [NDI]) had between 12% (95% CI: 7-18%) and 28% (25-32%) lower odds of treatment dispense over the time periods studied compared to the lower third of NDI distribution, even after accounting for demographic and clinical characteristics. A limited chart review (N = 40) confirmed that in some cases a decision not to treat was appropriate and aligned with national guidelines to use clinical judgement on a case-by-case basis. There is a need to enhance patient and provider awareness on the availability and benefits of nirmatrelvir-ritonavir for the treatment of COVID-19 illness. Nirmatrelvir is an oral antiviral that, when co-administered with ritonavir within 5 days of symptom onset, is highly effective at reducing the risk of hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for progression to severe disease 1-6 . Accordingly, nirmatrelvir-ritonavir received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) in December 2021. Nirmatrelvir-ritonavir treatment eligibility depends on the presence of underlying risk factors for progression to severe COVID-19 including age and vaccination status, weight, renal and hepatic function, and current use of select medications known to interact with nirmatrelvir-ritonavir. In the United States, initial guidelines recommended a tiered prioritization approach to treatment based on clinical risk 7 . As knowledge and treatment availability expanded throughout 2022, recommendations adapted to widen treatment eligibility criteria, eventually including all persons aged 65 years and older or aged 12 years and older with one or more clinical risk factors for progression to severe COVID-19. More recently (i.e., after our study period), treatment eligibility criteria have expanded further to include all adults aged..
Author contributions DM constructed the analysis plan, assisted with the analysis and drafted the manuscript. DM, SYT, JAL, BKA, LP, VH, JS and JMM designed the project. VH completed the programming and data analysis. All authors revised the manuscript and provided critical input.
Competing interests JAL has received grants and consultancy fees from Pfizer. SYT and TF have received grants from Pfizer paid directly to their institution. LP and JMM are employees of Pfizer and hold stock and stock options in Pfizer. BKA receives research support from Dynavax, Moderna, GlaxoSmithKline, Pfizer and Genentech, for projects outside of the submitted work. JS has received grants from Pfizer, ALK Inc., Novavax and Dynavax Technologies paid directly to his institution. DM, VH and JK have no conflicts of interest to declare. This study was funded by Pfizer.
References
Aggarwal, Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: A retrospective cohort study, Lancet Infect. Dis
Appaneal, Nirmatrelvir/ritonavir utilization for the treatment of non-hospitalized adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System, Infect. Dis. Ther
Arbel, Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge, N. Engl. J. Med
Betsch, Wieler, Habersaat, Monitoring behavioural insights related to COVID-19, Lancet Public Health
Boehmer, Racial and ethnic disparities in outpatient treatment of COVID-19-United States, January-July 2022, MMWR Morb. Mortal. Wkly. Rep
Callaghan, Correlates and disparities of intention to vaccinate against COVID-19, Soc. Sci. Med
Davis, Comparing Kaiser Permanente members to the general population: Implications for generalizability of research, Perm. J
Dorn, Cooney, Sabin, COVID-19 exacerbating inequalities in the US, Lancet
Dryden-Peterson, Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system, Ann. Intern. Med
Fda, PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers
Floyd, COVID-19 vaccination and mask wearing behaviors in the United States, August 2020-June 2021, Expert Rev. Vaccines
Ganatra, Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19, Clin. Infect. Dis
Glasheen, Charlson comorbidity index: ICD-9 update and ICD-10 translation, Am. Health Drug Benefits
Gold, Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability-United States, December 23, 2021, MMWR Morb. Mortal. Wkly. Rep
Hammond, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N. Engl. J. Med
Jefferson, Differences in COVID-19 testing and adverse outcomes by race, ethnicity, sex, and health system setting in a large diverse US cohort, PLoS One
Lewnard, Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: A cohort study in a large US health-care system, Lancet Infect. Dis
Lindholt, Jørgensen, Bor, Petersen, Public acceptance of COVID-19 vaccines: Cross-national evidence on levels and individual-level predictors using observational data, BMJ Open
Magesh, Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status, JAMA Netw. Open
Malden, Natural language processing for improved characterization of COVID-19 symptoms: Observational study of 350,000 patients in a large integrated health care system, JMIR Public Health Surveill
Manciulli, Safety and efficacy of outpatient treatments for COVID-19: Real-life data from a regionwide cohort of high-risk patients in Tuscany, Italy (the FEDERATE Cohort), Viruses
Mclaughlin, County-level predictors of coronavirus disease 2019 (COVID-19) cases and deaths in the United States: What happened, and where do we go from here?, Clin. Infect. Dis
Messer, The development of a standardized neighborhood deprivation index, J. Urban Health
Murphy, Samson, Sommers, COVID-19 Antivirals Utilization: Geographic and Demographic Patterns of Treatment in
Najjar-Debbiny, Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients, Clin. Infect. Dis
O'hayer, Evolution of care and outcomes across surges in hospitalized patients with coronavirus disease 2019, Am. J. Med
Shah, Paxlovid associated with decreased hospitalization rate among adults with COVID-19-United States, April-September 2022, Am. J. Transplant
Sullivan, Notes from the field: Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability-United States, December 23, 2021, MMWR Morb. Mortal. Wkly. Rep
Wong, Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study, Lancet
Yip, Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients, Clin. Infect. Dis
{ 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T01:15:15Z', 'timestamp': 1711761315325},
'reference-count': 34,
'publisher': 'Springer Science and Business Media LLC',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2024, 3, 29]],
'date-time': '2024-03-29T00:00:00Z',
'timestamp': 1711670400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'},
{ 'start': { 'date-parts': [[2024, 3, 29]],
'date-time': '2024-03-29T00:00:00Z',
'timestamp': 1711670400000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'}],
'funder': [{'DOI': '10.13039/100004319', 'name': 'Pfizer', 'doi-asserted-by': 'publisher'}],
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'abstract': '<jats:title>Abstract</jats:title><jats:p>A clear understanding of real-world uptake of '
'nirmatrelvir–ritonavir for treatment of SARS-CoV-2 can inform treatment allocation strategies '
'and improve interpretation of effectiveness studies. We used data from a large US healthcare '
'system to describe nirmatrelvir–ritonavir dispenses among all SARS-CoV-2 positive patients '
'aged ≥\u200912\xa0years meeting recommended National Institutes of Health treatment '
'eligibility criteria for the study period between 1 January and 31 December, 2022. Overall, '
'10.9% (N\u2009=\u200934,791/319,900) of treatment eligible patients with SARS-CoV-2 '
'infections received nirmatrelvir–ritonavir over the study period. Although uptake of '
'nirmatrelvir–ritonavir increased over time, by the end of 2022, less than a quarter of '
'treatment eligible patients with SARS-CoV-2 infections had received nirmatrelvir–ritonavir. '
'Across patient demographics, treatment was generally consistent with tiered treatment '
'guidelines, with dispenses concentrated among patients aged\u2009≥\u200965\xa0years '
'(14,706/63,921; 23.0%), and with multiple comorbidities (10,989/54,431; 20.1%). However, '
'neighborhoods of lower socioeconomic status (upper third of neighborhood deprivation index '
'[NDI]) had between 12% (95% CI: 7–18%) and 28% (25–32%) lower odds of treatment dispense over '
'the time periods studied compared to the lower third of NDI distribution, even after '
'accounting for demographic and clinical characteristics. A limited chart review (N\u2009'
'=\u200940) confirmed that in some cases a decision not to treat was appropriate and aligned '
'with national guidelines to use clinical judgement on a case-by-case basis. There is a need '
'to enhance patient and provider awareness on the availability and benefits of '
'nirmatrelvir–ritonavir for the treatment of COVID-19 illness.</jats:p>',
'DOI': '10.1038/s41598-024-57633-7',
'type': 'journal-article',
'created': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T10:01:53Z', 'timestamp': 1711706513000},
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system',
'prefix': '10.1038',
'volume': '14',
'author': [ {'given': 'Deborah E.', 'family': 'Malden', 'sequence': 'first', 'affiliation': []},
{'given': 'John M.', 'family': 'McLaughlin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Vennis', 'family': 'Hong', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joseph', 'family': 'Lewnard', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bradley K.', 'family': 'Ackerson', 'sequence': 'additional', 'affiliation': []},
{'given': 'Laura', 'family': 'Puzniak', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jeniffer S.', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []},
{'given': 'Harpreet', 'family': 'Takhar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Timothy B.', 'family': 'Frankland', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jeff M.', 'family': 'Slezak', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sara Y.', 'family': 'Tartof', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2024, 3, 29]]},
'reference': [ { 'issue': '9',
'key': '57633_CR1',
'doi-asserted-by': 'publisher',
'first-page': '790',
'DOI': '10.1056/NEJMoa2204919',
'volume': '387',
'author': 'R Arbel',
'year': '2022',
'unstructured': 'Arbel, R. et al. Nirmatrelvir use and severe Covid-19 outcomes during '
'the omicron surge. N. Engl. J. Med. 387(9), 790–798 (2022).',
'journal-title': 'N. Engl. J. Med.'},
{ 'issue': '1',
'key': '57633_CR2',
'doi-asserted-by': 'publisher',
'first-page': '77',
'DOI': '10.7326/M22-2141',
'volume': '176',
'author': 'S Dryden-Peterson',
'year': '2023',
'unstructured': 'Dryden-Peterson, S. et al. Nirmatrelvir plus ritonavir for early '
'COVID-19 and hospitalization in a large US health system. Ann. Intern. '
'Med. 176(1), 77–84 (2023).',
'journal-title': 'Ann. Intern. Med.'},
{ 'issue': '15',
'key': '57633_CR3',
'doi-asserted-by': 'publisher',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'volume': '386',
'author': 'J Hammond',
'year': '2022',
'unstructured': 'Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized '
'adults with Covid-19. N. Engl. J. Med. 386(15), 1397–1408 (2022).',
'journal-title': 'N. Engl. J. Med.'},
{ 'issue': '7',
'key': '57633_CR4',
'doi-asserted-by': 'publisher',
'first-page': '806',
'DOI': '10.1016/S1473-3099(23)00118-4',
'volume': '23',
'author': 'JA Lewnard',
'year': '2023',
'unstructured': 'Lewnard, J. A. et al. Effectiveness of nirmatrelvir–ritonavir in '
'preventing hospital admissions and deaths in people with COVID-19: A '
'cohort study in a large US health-care system. Lancet Infect. Dis. '
'23(7), 806–815 (2023).',
'journal-title': 'Lancet Infect. Dis.'},
{ 'issue': '3',
'key': '57633_CR5',
'doi-asserted-by': 'publisher',
'first-page': 'e342',
'DOI': '10.1093/cid/ciac443',
'volume': '76',
'author': 'R Najjar-Debbiny',
'year': '2023',
'unstructured': 'Najjar-Debbiny, R. et al. Effectiveness of paxlovid in reducing severe '
'coronavirus disease 2019 and mortality in high-risk patients. Clin. '
'Infect. Dis. 76(3), e342–e349 (2023).',
'journal-title': 'Clin. Infect. Dis.'},
{ 'issue': '10359',
'key': '57633_CR6',
'doi-asserted-by': 'publisher',
'first-page': '1213',
'DOI': '10.1016/S0140-6736(22)01586-0',
'volume': '400',
'author': 'CKH Wong',
'year': '2022',
'unstructured': 'Wong, C. K. H. et al. Real-world effectiveness of molnupiravir and '
'nirmatrelvir plus ritonavir against mortality, hospitalisation, and '
'in-hospital outcomes among community-dwelling, ambulatory patients with '
'confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An '
'observational study. Lancet 400(10359), 1213–1222 (2022).',
'journal-title': 'Lancet'},
{ 'key': '57633_CR7',
'volume-title': 'Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of '
'COVID-19 in Nonhospitalized Patients When There Are Logistical '
'Constraints',
'author': 'NIH',
'year': '2022',
'unstructured': 'NIH. Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of '
'COVID-19 in Nonhospitalized Patients When There Are Logistical '
'Constraints (National Institutes of Health, 2022).'},
{ 'issue': '11',
'key': '57633_CR8',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2021.34147',
'volume': '4',
'author': 'S Magesh',
'year': '2021',
'unstructured': 'Magesh, S. et al. Disparities in COVID-19 outcomes by race, ethnicity, '
'and socioeconomic status. JAMA Netw. Open 4(11), e2134147 (2021).',
'journal-title': 'JAMA Netw. Open'},
{ 'key': '57633_CR9',
'doi-asserted-by': 'publisher',
'first-page': '1359',
'DOI': '10.15585/mmwr.mm7143a2',
'volume': '71',
'author': 'TK Boehmer',
'year': '2022',
'unstructured': 'Boehmer, T. K. et al. Racial and ethnic disparities in outpatient '
'treatment of COVID-19—United States, January–July 2022. MMWR Morb. '
'Mortal. Wkly. Rep 71, 1359–1365 (2022).',
'journal-title': 'MMWR Morb. Mortal. Wkly. Rep'},
{ 'issue': '4',
'key': '57633_CR10',
'doi-asserted-by': 'publisher',
'first-page': '563',
'DOI': '10.1093/cid/ciac673',
'volume': '76',
'author': 'S Ganatra',
'year': '2022',
'unstructured': 'Ganatra, S. et al. Oral nirmatrelvir and ritonavir in non-hospitalized '
'vaccinated patients with Covid-19. Clin. Infect. Dis. 76(4), 563–572 '
'(2022).',
'journal-title': 'Clin. Infect. Dis.'},
{ 'issue': '3',
'key': '57633_CR11',
'doi-asserted-by': 'publisher',
'first-page': '26',
'DOI': '10.1093/cid/ciac687',
'volume': '76',
'author': 'T Yip',
'year': '2022',
'unstructured': 'Yip, T. et al. Impact of the use of oral antiviral agents on the risk of '
'hospitalization in community COVID-19 patients. Clin. Infect. Dis. '
'76(3), 26-e33 (2022).',
'journal-title': 'Clin. Infect. Dis.'},
{ 'issue': '2',
'key': '57633_CR12',
'doi-asserted-by': 'publisher',
'first-page': '87',
'DOI': '10.7812/TPP/22.172',
'volume': '27',
'author': 'A Davis',
'year': '2023',
'unstructured': 'Davis, A. et al. Comparing Kaiser Permanente members to the general '
'population: Implications for generalizability of research. Perm. J. '
'27(2), 87–92 (2023).',
'journal-title': 'Perm. J.'},
{ 'key': '57633_CR13',
'unstructured': 'Underlying Medical Conditions Associated with Higher Risk for Severe '
'COVID-19: Information for Healthcare Professionals. '
'https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html '
'(2023).'},
{ 'key': '57633_CR14',
'unstructured': 'Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) '
'and Concomitant Medications. '
'https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/ '
'(2023).'},
{ 'key': '57633_CR15',
'unstructured': 'FDA. PAXLOVID Patient Eligibility Screening Checklist Tool for '
'Prescribers. February 19th 2024. '
'https://www.fda.gov/media/158165/download (2022).'},
{ 'issue': '6',
'key': '57633_CR16',
'doi-asserted-by': 'publisher',
'first-page': '1041',
'DOI': '10.1007/s11524-006-9094-x',
'volume': '83',
'author': 'LC Messer',
'year': '2006',
'unstructured': 'Messer, L. C. et al. The development of a standardized neighborhood '
'deprivation index. J. Urban Health 83(6), 1041–1062 (2006).',
'journal-title': 'J. Urban Health'},
{ 'issue': '12',
'key': '57633_CR17',
'doi-asserted-by': 'publisher',
'DOI': '10.2196/41529',
'volume': '8',
'author': 'DE Malden',
'year': '2022',
'unstructured': 'Malden, D. E. et al. Natural language processing for improved '
'characterization of COVID-19 symptoms: Observational study of 350,000 '
'patients in a large integrated health care system. JMIR Public Health '
'Surveill. 8(12), e41529 (2022).',
'journal-title': 'JMIR Public Health Surveill.'},
{ 'issue': '4',
'key': '57633_CR18',
'first-page': '188',
'volume': '12',
'author': 'WP Glasheen',
'year': '2019',
'unstructured': 'Glasheen, W. P. et al. Charlson comorbidity index: ICD-9 update and '
'ICD-10 translation. Am. Health Drug Benefits 12(4), 188–197 (2019).',
'journal-title': 'Am. Health Drug Benefits'},
{ 'issue': '1',
'key': '57633_CR19',
'doi-asserted-by': 'publisher',
'first-page': '155',
'DOI': '10.1007/s40121-023-00910-1',
'volume': '13',
'author': 'HJ Appaneal',
'year': '2024',
'unstructured': 'Appaneal, H. J. et al. Nirmatrelvir/ritonavir utilization for the '
'treatment of non-hospitalized adults with COVID-19 in the National '
'Veterans Affairs (VA) Healthcare System. Infect. Dis. Ther. 13(1), '
'155–172 (2024).',
'journal-title': 'Infect. Dis. Ther.'},
{ 'issue': '6',
'key': '57633_CR20',
'doi-asserted-by': 'publisher',
'first-page': '696',
'DOI': '10.1016/S1473-3099(23)00011-7',
'volume': '23',
'author': 'NR Aggarwal',
'year': '2023',
'unstructured': 'Aggarwal, N. R. et al. Real-world use of nirmatrelvir–ritonavir in '
'outpatients with COVID-19 during the era of omicron variants including '
'BA.4 and BA.5 in Colorado, USA: A retrospective cohort study. Lancet '
'Infect. Dis. 23(6), 696–705 (2023).',
'journal-title': 'Lancet Infect. Dis.'},
{ 'issue': '11',
'key': '57633_CR21',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0276742',
'volume': '17',
'author': 'C Jefferson',
'year': '2022',
'unstructured': 'Jefferson, C. et al. Differences in COVID-19 testing and adverse '
'outcomes by race, ethnicity, sex, and health system setting in a large '
'diverse US cohort. PLoS\xa0One 17(11), e0276742 (2022).',
'journal-title': 'PLoS\xa0One'},
{ 'key': '57633_CR22',
'doi-asserted-by': 'publisher',
'first-page': '825',
'DOI': '10.15585/mmwr.mm7125e1',
'volume': '71',
'author': 'JA Gold',
'year': '2022',
'unstructured': 'Gold, J. A. et al. Dispensing of oral antiviral drugs for treatment of '
'COVID-19 by zip code-level social vulnerability—United States, December '
'23, 2021–May 21, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 825–829 (2022).',
'journal-title': 'MMWR Morb. Mortal. Wkly. Rep.'},
{ 'issue': '43',
'key': '57633_CR23',
'doi-asserted-by': 'publisher',
'first-page': '1384',
'DOI': '10.15585/mmwr.mm7143a3',
'volume': '28',
'author': 'M Sullivan',
'year': '2022',
'unstructured': 'Sullivan, M. et al. Notes from the field: Dispensing of oral antiviral '
'drugs for treatment of COVID-19 by zip code-level social '
'vulnerability—United States, December 23, 2021–August 28, 2022. MMWR '
'Morb. Mortal. Wkly. Rep. 28(43), 1384–1385 (2022).',
'journal-title': 'MMWR Morb. Mortal. Wkly. Rep.'},
{ 'issue': '10232',
'key': '57633_CR24',
'doi-asserted-by': 'publisher',
'first-page': '1243',
'DOI': '10.1016/S0140-6736(20)30893-X',
'volume': '395',
'author': 'AV Dorn',
'year': '2020',
'unstructured': 'Dorn, A. V., Cooney, R. E. & Sabin, M. L. COVID-19 exacerbating '
'inequalities in the US. Lancet 395(10232), 1243–1244 (2020).',
'journal-title': 'Lancet'},
{ 'issue': '7',
'key': '57633_CR25',
'doi-asserted-by': 'publisher',
'first-page': 'e1814',
'DOI': '10.1093/cid/ciaa1729',
'volume': '73',
'author': 'JM McLaughlin',
'year': '2021',
'unstructured': 'McLaughlin, J. M. et al. County-level predictors of coronavirus disease '
'2019 (COVID-19) cases and deaths in the United States: What happened, '
'and where do we go from here?. Clin. Infect. Dis. 73(7), e1814–e1821 '
'(2021).',
'journal-title': 'Clin. Infect. Dis.'},
{ 'key': '57633_CR26',
'unstructured': 'Disparities in the risk and outcomes of COVID-19. 19th February 2024. '
'https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/908434/Disparities_in_the_risk_and_outcomes_of_COVID_August_2020_update.pdf '
'(2020).'},
{ 'issue': '2',
'key': '57633_CR27',
'doi-asserted-by': 'publisher',
'first-page': '438',
'DOI': '10.3390/v15020438',
'volume': '15',
'author': 'T Manciulli',
'year': '2023',
'unstructured': 'Manciulli, T. et al. Safety and efficacy of outpatient treatments for '
'COVID-19: Real-life data from a regionwide cohort of high-risk patients '
'in Tuscany, Italy (the FEDERATE Cohort). Viruses 15(2), 438 (2023).',
'journal-title': 'Viruses'},
{ 'key': '57633_CR28',
'unstructured': 'Murphy, S., Samson, L. W. & Sommers, B. D. COVID-19 Antivirals '
'Utilization: Geographic and Demographic Patterns of Treatment in 2022, '
'19th February 2024. '
'https://aspe.hhs.gov/sites/default/files/documents/a19600d0dccfee0e9c595730d73fd66d/covid-antivirals-report.pdf '
'(2022).'},
{ 'issue': '10232',
'key': '57633_CR29',
'first-page': '1255',
'volume': '395',
'author': 'C Betsch',
'year': '2020',
'unstructured': 'Betsch, C., Wieler, L. H. & Habersaat, K. Monitoring behavioural '
'insights related to COVID-19. Lancet Public Health 395(10232), 1255–1256 '
'(2020).',
'journal-title': 'Lancet Public Health'},
{ 'key': '57633_CR30',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.socscimed.2020.113638',
'volume': '272',
'author': 'T Callaghan',
'year': '2021',
'unstructured': 'Callaghan, T. et al. Correlates and disparities of intention to '
'vaccinate against COVID-19. Soc. Sci. Med. 272, 113638 (2021).',
'journal-title': 'Soc. Sci. Med.'},
{ 'issue': '6',
'key': '57633_CR31',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmjopen-2020-048172',
'volume': '11',
'author': 'MF Lindholt',
'year': '2021',
'unstructured': 'Lindholt, M. F., Jørgensen, F., Bor, A. & Petersen, M. B. Public '
'acceptance of COVID-19 vaccines: Cross-national evidence on levels and '
'individual-level predictors using observational data. BMJ Open 11(6), '
'e048172 (2021).',
'journal-title': 'BMJ Open'},
{ 'issue': '10',
'key': '57633_CR32',
'doi-asserted-by': 'publisher',
'first-page': '1487',
'DOI': '10.1080/14760584.2022.2104251',
'volume': '21',
'author': 'CJ Floyd',
'year': '2022',
'unstructured': 'Floyd, C. J. et al. COVID-19 vaccination and mask wearing behaviors in '
'the United States, August 2020–June 2021. Expert Rev. Vaccines 21(10), '
'1487–1493 (2022).',
'journal-title': 'Expert Rev. Vaccines'},
{ 'issue': '1',
'key': '57633_CR33',
'doi-asserted-by': 'publisher',
'first-page': '63',
'DOI': '10.1016/j.amjmed.2022.08.035',
'volume': '136',
'author': "PJ O'Hayer",
'year': '2023',
'unstructured': 'O’Hayer, P. J. et al. Evolution of care and outcomes across surges in '
'hospitalized patients with coronavirus disease 2019. Am. J. Med. 136(1), '
'63–71 (2023).',
'journal-title': 'Am. J. Med.'},
{ 'issue': '1',
'key': '57633_CR34',
'doi-asserted-by': 'publisher',
'first-page': '150',
'DOI': '10.1016/j.ajt.2022.12.004',
'volume': '23',
'author': 'MM Shah',
'year': '2023',
'unstructured': 'Shah, M. M. et al. Paxlovid associated with decreased hospitalization '
'rate among adults with COVID-19—United States, April–September 2022. Am. '
'J. Transplant. 23(1), 150–155 (2023).',
'journal-title': 'Am. J. Transplant.'}],
'container-title': 'Scientific Reports',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.nature.com/articles/s41598-024-57633-7.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41598-024-57633-7',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41598-024-57633-7.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 3, 29]],
'date-time': '2024-03-29T10:03:34Z',
'timestamp': 1711706614000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-024-57633-7'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 3, 29]]},
'references-count': 34,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}},
'alternative-id': ['57633'],
'URL': 'http://dx.doi.org/10.1038/s41598-024-57633-7',
'relation': {},
'ISSN': ['2045-2322'],
'subject': ['Multidisciplinary'],
'container-title-short': 'Sci Rep',
'published': {'date-parts': [[2024, 3, 29]]},
'assertion': [ { 'value': '27 July 2023',
'order': 1,
'name': 'received',
'label': 'Received',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '20 March 2024',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '29 March 2024',
'order': 3,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'JAL has received grants and consultancy fees from Pfizer. SYT and TF have '
'received grants from Pfizer paid directly to their institution. LP and JMM are '
'employees of Pfizer and hold stock and stock options in Pfizer. BKA receives '
'research support from Dynavax, Moderna, GlaxoSmithKline, Pfizer and Genentech, '
'for projects outside of the submitted work. JS has received grants from Pfizer, '
'ALK Inc., Novavax and Dynavax Technologies paid directly to his institution. '
'DM, VH and JK have no conflicts of interest to declare. This study was funded '
'by Pfizer.',
'order': 1,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}],
'article-number': '7485'}
